Induction of tumor-specific immunity in mice by immunization with reconstituted tumor membrane liposomes containing recombinant B7-2 (CD86)

Journal of Immunotherapy

Volumn 23, Issue 4, 2000, Pages 456-463

  Westerman, Larry E ^a   Sund, Solomon C ^a   Selvaraj, Periasamy ^a   Jensen, Peter E ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cancer; Costimulation; Immunotherapy; Liposome; Vaccine

Indexed keywords

CD86 ANTIGEN; LIPOSOME;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; FIBROSARCOMA; IMMUNIZATION; IMMUNOGENICITY; IMMUNOPHARMACOLOGY; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR REJECTION;

ANIMALS; ANTIGENS, CD; ANTIGENS, CD86; CANCER VACCINES; CELL MEMBRANE; CYTOTOXICITY TESTS, IMMUNOLOGIC; FIBROSARCOMA; LIPOSOMES; MELANOMA, EXPERIMENTAL; MEMBRANE GLYCOPROTEINS; MICE; RECOMBINANT PROTEINS; T-LYMPHOCYTES, CYTOTOXIC; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 0033948423     PISSN: 10538550     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002371-200007000-00009     Document Type: Article

References (37)

1. Boon T, Cerottini JC, Van den Eynde B, van der Bruggen P, Van Pel A. Tumor antigens recognized by T lymphocytes. Annu Rev Immunol 1994;12:337-65.
2. Sogn JA. Tumor immunology: the glass is half full. Immunity 1998;9:757-63.
3. Pardoll DM. Paracrine cytokine adjuvants in cancer immunotherapy. Annu Rev Immunol 1995;13:399-415.
4. Huang AYC, Golumbek P, Ahmadzadeh M, et al. Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. Science 1994;264:961-5.
5. Suto R, Srivastava PK. A mechanism for the specific immunogenicity of heat shock protein-chaperoned peptides. Science 1995; 269:1585-8.
6. Ashley DM, Faiola B, Nair S, et al. Bone marrow-generated dendritic cells pulsed with tumor extracts or tumor RNA induce anti-tumor immunity against central nervous system tumors. J Exp Med 1997;186:1177-82.
7. Fields RC, Shimizu K, Mule JJ. Murine dendritic cells pulsed with whole tumor lysates mediate potent antitumor immune responses in vitro and in vivo. Proc Natl Acad Sci U S A 1998;95:9482-7.
8. + T cells by B7-transfected melanoma cells. Science 1993;259:368-70.
9. Chen L, Ashe S, Brady WA, et al. Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4. Cell 1992;71:1093-102.
10. Ramarathinam L, Castle M, Wu Y, Liu Y. T cell costimulation by B7/BB1 induces CD8 T cell-dependent tumor rejection: an important role of B7/BB1 in the induction, recruitment, and effector function of antitumor T cells. J Exp Med 1994;179:1205-14.
11. + T lymphocytes by B7, a natural ligand for CD28, can be used to treat established mouse melanoma. J Immunol 1994;153:421-8.
12. Chen L, McGowan P, Ashe S, et al. B7-1/CD80-transduced tumor cells elicit better systemic immunity than wild-type tumor cells admixed with Corynebacterium parvum. Cancer Res 1994;54: 5420-3.
13. Guo Y, Wu M, Chen H, et al. Effective tumor vaccine generated by fusion of hepatoma cells with activated B cells. Science 1994;263: 518-20.
14. Yang G, Hellstrom KE, Hellstrom I, Chen L. Antitumor immunity elicited by tumor cells transfected with B7-2, a second ligand for CD28/CTLA-4 costimulatory molecules. J Immunol 1995;154: 2794-800.
15. Gong J, Chen D, Kashiwaba M, Kufe D. Induction of antitumor activity by immunization with fusions of dendritic and carcinoma cells. Nat Med 1997;3:558-61.
16. McHugh RS, Ahmed SN, Wang YC, Sell KW, Selvaraj P. Construction, purification, and functional incorporation on tumor cells of glycolipid-anchored human B7-1 (CD80). Proc Natl Acad Sci U S A 1995;92:8059-63.
17. Brunschwig EB, Levine E, Trefzer U, Tykocinski ML. Glycosylphosphatidylinositol-modified murine B7-1 and B7-2 retain costimulator function. J Immunol 1995;155:5498-505.
18. McHugh RS, Nagarajan S, Wang Y, Sell KW, Selvaraj P. Protein transfer of glycosyl-phosphatidylinositol-B7-1 into tumor cell membranes: a novel approach to tumor immunotherapy. Cancer Res 1999 59:2433-7.
19. Fidler IJ, Hart IR. Biological and experimental consequences of the zonal composition of solid tumors. Cancer Res 1981;41:3266-7.
20. Ward PL, Koeppen H, Hurteau T, Schreiber H. Tumor antigens defined by cloned immunological probes are highly polymorphic and are not detected on autologous normal cells. J Exp Med 1989; 170:217-32.
21. O'Reilly DR, Miller LK, Luckow VA. Baculovirus Expression Vectors: A Laboratory Manual. New York: Oxford University Press, 1994;107-234.
22. Jensen PE. Enhanced binding of peptide antigen to purified class II major histocompatibility glycoproteins at acidic pH. J Exp Med 1991;174:1111-20.
23. Freeman GJ, Bordello F, Hodes RJ, et al.Murine B7-2, an alternative CTLA4 counter-receptor that costimulates T cell proliferation and interleukin 2 production. J Exp Med 1993;178:2185-92.
24. Hess HH, Derr JE. Assay of inorganic and organic phosphorus in the 0.1-5 nanomole range. Ann Biochem 1975;63:607-13.
25. Silvius JR. Solubilization and functional reconstitution of biomembrane components. Annu Rev Biophys Biomol Struct 1992;21: 323-48.
26. Sherman MA, Rannels HA, Moore JC, Stern LJ, Jensen PE. Membrane interactions influence the peptide binding behavior of DR1. J Exp Med 1994;179:229-34.
27. Wick M, Dubey P, Koeppen H, et al. Antigenic cancer cells grow progressively in immune hosts without evidence for T cell exhaustion or systemic anergy. J Exp Med 1997;186:229-38.
28. Li Y, Hellstrom KE, Newby SA, Chen L. Costimulation by CD48 and B7-1 induces immunity against poorly immunogenic tumors. J Exp Med 1996;183:639-44.
29. Chen L, McGowan P, Ashe S, et al. Tumor immunogenicity determines the effect of B7 costimulation on T cell-mediated tumor immunity. J Exp Med 1994;179:523-32.
30. Melero I, Shuford WW, Newby SA, et al. Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors. Proc Natl Acad Sci USA 1997;94:6216-21.
31. + cytolytic T lymphocytes. J Exp Med 1996;183:791-800.
32. Matulonis U, Dosiou C, Freeman G, et al. B7-1 is superior to B7-2 costimulation in the induction and maintenance of T cell-mediated antileukemia immunity. Further evidence that B7-1 and B7-2 are functionally distinct. J Immunol 1996;156:1126-31.
33. Martin-Fontecha A, Cavallo F, Bellone M, et al. Heterogeneous effects of B7-1 and B7-2 in the induction of both protective and therapeutic anti-tumor immunity against different mouse tumors. Eur J Immunol 1996;26:1851-9.
34. + T lymphocytes in the P815 tumor system in vitro. J Immunol 1996; 156:465-72.
35. Greenfield EA, Howard E, Paradis T, et al. B7.2 expressed by T cells does not induce CD28-mediated costimulatory activity but retains CTLA4 binding: implications for induction of antitumor immunity to T cell tumors. J Immunol 1997;158:2025-34.
36. La Motte RN, Rubin MA, Barr E, et al. Therapeutic effectiveness of the immunity elicited by P815 tumor cells engineered to express the B7-2 costimulatory molecule. Cancer Immunol Immunother 1996;42:161-9.
37. Yu X, Abe R, Hodes RJ. The role of B7-CD28 co-stimulation in tumor rejection. Int Immunol 1998;10:791-7.